ReviewFrontiers in aging neuroscience2022
Genetic architecture of Parkinson's disease subtypes - Review of the literature.
Review in Frontiers in aging neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Beyond motor: a systematic review of multisensory integration deficits in Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2026Pooled it
- Omics research in Parkinson's disease: evolution, integrated analysis, pathogenic mechanisms, biomarkers, and therapeutic targets.Frontiers in molecular neuroscience · 2026Pooled it
- Proteins and Transcriptional Dysregulation of the Brain Extracellular Matrix in Parkinson's Disease: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Individualized Bayesian Inference Identifies Novel Genetic Variants for Parkinson's Disease.Genetic epidemiology · 2026Article
- Multi-omics approaches to parkinsonism: genomic, proteomic, and non-coding RNA perspectives.Molecular biology reports · 2026Review
- iSCORE-PD: an isogenic stem cell collection to research Parkinson's disease.Nature communications · 2026Article
- Stem Cell-Derived Exosomes Regulate Mitochondrial Function: A Novel Strategy for Parkinson's Disease Therapy.Molecular neurobiology · 2026Review
- Mondo: integrating disease terminology across communities.Genetics · 2026Article
- Prognostic Value of Parkinson's Disease Subtypes in the LABS-PD Cohort: Functional Ability, Quality of Life and Mortality.Movement disorders clinical practice · 2026Article
- Evolution of disease modifying therapy clinical trial design and therapeutic endpoints for Parkinson's disease.Journal of Parkinson's disease · 2026Review
- Prediction of impulse control disorders in Parkinson's disease through a longitudinal machine learning study.NPJ Parkinson's disease · 2026Article
- Carriers of LRRK2 pathogenic variants show a milder, anatomically distinct brain signature of Parkinson's disease.Communications medicine · 2026Article
- Article
- Inflammation and neuropsychiatric symptoms in Parkinson's disease: a genetic association.Frontiers in aging neuroscience · 2026Article
- Whole-exome sequencing and burden analysis identify six novel candidate risk genes and expand the genetic landscape of Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Proximity to Golf Courses and Risk of Parkinson Disease.JAMA network open · 2025Article
- Large-fiber neuropathy in Parkinson's disease: a narrative review.Neurological research and practice · 2024Review
- Associations of cholinergic system integrity with cognitive decline in GBA1 and LRRK2 mutation carriers.NPJ Parkinson's disease · 2024Article
- Neurocognitive Impairment and Social Cognition in Parkinson's Disease Patients.Neurology international · 2024Review
- Targeting Mitochondrial Complex I Deficiency in MPPBiological procedures online · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The heterogeneity of Parkinson's disease (PD) has been recognized since its description by James Parkinson over 200 years ago. The complexity of motor and non-motor PD manifestations has led to many attempts of PD subtyping with different prognostic outcomes; however, the pathophysiological foundations of PD heterogeneity remain elusive. Genetic contributions to PD may be informative in understanding the underpinnings of PD subtypes. As such, recognizing genotype-phenotype associations may be crucial for successful gene therapy. We review the state of knowledge on the genetic architecture underlying PD subtypes, discussing the monogenic forms, as well as oligo- and polygenic risk factors associated with various PD subtypes. Based on our review, we argue for the unification of PD subtyping classifications, the dichotomy of studies on genetic factors and genetic modifiers of PD, and replication of results from previous studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.